Clinical categories where the outcome depends on the quality of the argument.
Specialty denials require specialty-specific evidence frameworks, society guidelines, and compendia grading — not generic medical-necessity narrative.
Applications of the core deliverables — not separate products.
Specialty matters are handled through the same fixed-format deliverables — the Escalation Memo, the Pre-Denial Dossier, the P2P Brief, and AI Appeal Clinical QA — applied with the evidence chain the specialty actually requires. What changes is the framework: the precise combination of guideline, compendium, label, measurement, and payer-policy alignment on which each specialty’s coverage decisions turn.
The competence boundary. Where a dispute requires deep subspecialty judgment or a formal expert attestation, Clinovian declines the matter or names an appropriately qualified approved contributor in the scope — before records are transferred, not after.
The coverage decision is a precision match.
Oncology coverage can depend on an exact alignment among diagnosis and subtype, biomarker status, stage, line of therapy, prior treatment and response or intolerance, dose and schedule, FDA labeling, recognized compendia, and the specific payer policy. CMS identifies recognized compendia relevant to certain off-label anticancer drug coverage — which is why the evidence source and the indication details matter, and why commercial and Medicare Advantage policies are checked separately rather than assumed equivalent.
What the analysis organizes
- Case chronology: diagnosis, stage and subtype, biomarker, treatment history, response or intolerance, and the requested therapy
- Mapping to client-authorized guidelines, compendia, label, and payer policy
- The exact unmet criterion, evidence conflicts, and documentation gaps
- Clinical handoff for an appeal, P2P, or pre-authorization team
Not an oncology consultation, treatment recommendation, formulary guarantee, or substitute for the treating oncologist’s documentation.
Quantitative thresholds and the sequence behind them.
Cardiology decisions often turn on measurements and a documented sequence of prior evaluation or treatment: symptom class, hemodynamics, imaging, functional limitation, failed conservative pathways, device indications, and contraindications. A generic narrative loses precisely because it omits the exact measurement, date, symptom class, or exception that controls the coverage rule.
What the analysis organizes
- Time-ordered symptoms, objective results, interventions, and response
- An evidence-to-policy map with units, dates, and source location where available
- Failed alternatives, contraindications, acuity, and setting
- A direct response to the payer rationale, with writer and P2P handoff
Complementary to — not a substitute for — a treating cardiologist, physician advisor, or coding professional.
The documented sequence is the argument.
Orthopedic policies frequently require a specific chain: symptom duration and severity, objective examination findings, imaging concordance, failed conservative therapy with modality and adherence, functional impact, and the surgical indication — often with post-acute needs attached. Missing dates, duration, adherence, or response can undermine an otherwise reasonable request. The work is disciplined documentation sequencing, not restating pain and imaging.
What the analysis organizes
- Chronology of symptoms, function, testing, conservative care, and response
- A direct evidence map to the authorized policy
- Missing duration, modality, adherence, or imaging-correlation evidence, identified explicitly
- Appeal, P2P, or pre-denial handoff with adverse facts and risk
A clinical support document — it cannot replace the surgeon’s examination, recommendation, or any required attestation.
The decisive facts are scattered across years of records.
Neurologic disputes — drugs, imaging, procedures, devices, rehabilitation, level of care — can involve longitudinal disease activity, subtle functional evidence, step therapy, rare conditions, and high-cost treatment pathways. The useful role here is synthesis: pulling disease course, treatment failures and intolerance, biomarkers, and relapse activity out of a fragmented longitudinal record into a chronology with source traceability.
What the analysis organizes
- A longitudinal clinical and treatment timeline
- An evidence map to the client-approved policy and guideline sources
- Disease activity, function, treatment failure or intolerance, and applicable exceptions
- Missing-evidence and risk analysis, plus appeal or P2P handoff
Rare-disease, subspecialty-device, or contested-treatment disputes may require an approved specialist contributor — or a decline.
Level of care turns on more than diagnosis.
Inpatient psychiatric, residential, partial hospitalization, intensive outpatient, substance-use, and ongoing-service disputes depend on current risk, functional impairment, treatment intensity, response, and the feasibility of a safe lower level — documented, not asserted. CMS also requires certification and recertification elements for covered inpatient psychiatric services, which illustrates the limit of narrative: a strong argument cannot replace required formal documentation.
What the analysis organizes
- Time-ordered risk, function, symptoms, interventions, response, and discharge readiness
- An evidence map to an authorized level-of-care pathway
- Lower-level alternative analysis, missing documents, and adverse evidence
- A handoff for the client’s authorized appeal or UM team
Clinical-necessity support only. Mental-health parity analysis (MHPAEA), benefit interpretation, and legal strategy remain with qualified counsel. No diagnosis, treatment plan, certification, or treating-clinician role.
SNF / IRF / LTACH / home health.
Criteria-heavy, frequently disputed, and specifically scrutinized in federal oversight reports for high appeal-overturn patterns. Post-acute work has its own dedicated service page covering all four settings and the oversight data behind them.
Specialty matters are quoted after a de-identified scope review — the record burden, the number of evidence sources, and the policy complexity drive the fee. The standard product fee (P2P Preparation Brief from $300, AI Appeal Clinical QA from $250, standard physician denial review from $450) applies only when the specialty burden stays within that product’s standard scope.
Financial exposure in specialty disputes varies by payer, contract, geography, coding, case, and payment methodology. Use the actual remittance and contract amounts — not generic ranges — to assess whether physician review is economical for a given matter.
Five specialties. Five distinct evidence chains.
The pages remain applications of the core services—not claims of board-specialty practice. Each explains the evidence map, required inputs, common failure modes, and the point at which a specialist opinion is required.
Oncology Support
Diagnosis, stage, biomarker, treatment line, prior therapy, evidence source, dose, and policy.
Cardiology Support
Symptoms, function, objective testing, hemodynamics, treatment sequence, intervention, and setting.
Orthopedic Support
Duration, function, examination, imaging, conservative care, exception, and procedure.
Neurology Support
Longitudinal disease activity, objective testing, function, and treatment history.
Behavioral-Health Support
Current risk, function, intensity, response, discharge readiness, and safe lower levels.
Specialist judgment remains specialist work.
Diagnosis, treatment advice, formal specialty opinion, expert testimony, and licensed attestation are not implied.
Send a specialty denial for suitability review.
One de-identified matter. Initial fit response in 24–48 hours.